Patents Assigned to Merck
  • Substituted pyridines as selective cyclooxygenase-2 inhibitors
    Patent number: 6596736
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. The invention also encompasses certain pharmaceutical compositions for treatment of COX-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: October 30, 2001
    Date of Patent: July 22, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Daniel Dube, Rejean Fortin, Richard Friesen, Zhaoyin Wang, Jacques Yves Gauthier
  • Electrooptical liquid crystal system
    Patent number: 6596193
    Abstract: To improve switching times, especially at low temperatures, one or more reactive liquid crystalline compounds is added to a liquid crystal mixture used in an electrooptical system. The electrooptical system comprises a PDLC film comprising a liquid crystal mixture forming micro- droplets in an optically isotropic, transparent polymer matrix between 2 electrode layers. The reactive liquid crystalline compounds are of formula II, R′—G′—R″, wherein R′, G′ and R″ are as defined herein. The liquid crystal mixture comprises one or more compounds of the formula I wherein R, A1, A2, Z1, Z2, X1, X2, Q, Y and n are as defined herein.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: July 22, 2003
    Assignee: Merck Patent GmbH
    Inventors: David Coates, Owain Llyr Parri, Simon Greenfield, Martin David Tillin, Mark John Goulding, Patrick Nolan
  • Aluminum alkyl complexes as cocatalysts
    Patent number: 6596890
    Abstract: Organometallic aluminum compounds of the general formula (I) where X1 is NH, NH2*, NH—A*, N—A, N(A)2*, O, OA*, O-Aryl*, S, SA*, P, P(A)2* or a single bond, X2 is NH, N—A, O, S, PA or X1 coordinated to Al(R1)3, or a single bond, R1 is H; Hal if n=0; A which may be covalently bound to Al; Si(A)3 if X1=O, R2 is A or divalent aryl groups defined note particularly below or divalent unsaturated aliphatic groups defined more particularly below, R3 and R4 are, independently of one another, a bond or R2 or Si(A)3 or Si(A)2, Z1 is a bond or H bound to R2, Z2 is a bond or H bound to R2 or R3, A is branched or unbranched C1-C7-alkyl, C1-C7-alkylidene or C1-C7-alkenylidene, Aryl is phenyl, naphthyl, Hal is F, Cl, and, independently of one another, n, m, p and l are 0 or 1 and q is 1 or 2, where &Sgr;l+m+n≧3.
    Type: Grant
    Filed: November 25, 1998
    Date of Patent: July 22, 2003
    Assignee: Merck Patent Gesellschaft
    Inventors: Eike Poetsch, Ludwig Pohl, Karin Weiss, Eva Maria Auth, Thomas Metzner, Herbert Schumann, Corinna Wassermann, Michael Frick, Bernd Heymer, Stefan Schutte, Ulf Dümichen, Elmar Hecht
  • Process for the preparation of UV filter substances
    Patent number: 6593476
    Abstract: The present invention relates to a preparation process for 2-arylbenzimidazolesulfonic acids of the formula I: Ar is a substituted or unsubstituted phenyl or naphthyl radical and R is a C1-8-alkyl or C1-8-alkoxy radical. n is 1-4, m is 1-3 and o is 0-2. o-phenylenediamine is reacted in the presence of oleum with an arylcarboxylic acid or an arylcarboxylic acid derivative. Compounds prepared in this way can be used as UV filters, and as components in cosmetic compositions.
    Type: Grant
    Filed: June 25, 2001
    Date of Patent: July 15, 2003
    Assignee: Merck Patent Gesellschaft mit beschränkter Haftung
    Inventors: Ulrich Heywang, Michael Schwarz, Frank Pflücker
  • Liquid-crystalline medium
    Patent number: 6592951
    Abstract: A liquid-crystalline medium based on a mixture of polar compounds having positive dielectric anisotropy, characterized in that it comprises one or more compounds of the general formula I in which R, A, L1, L2 and Y are as defined herein are suitable for use in liquid crystal displays such as MLC, TN or STN displays.
    Type: Grant
    Filed: March 23, 2001
    Date of Patent: July 15, 2003
    Assignee: Merck Patentgesellschaft
    Inventors: Michael Heckmeier, Brigitte Schuler, Peer Kirsch, Eike Poetsch
  • Pyrido-pyridazine derivatives as ligands for GABA receptors
    Patent number: 6593325
    Abstract: A class of pyrido[2,3-d]pyridazine derivatives, possessing an optionally substituted cycloalkyl, phenyl or heteroaryl substituent at the 8-position, a substituted alkoxy moiety at the 2-position, and a range of substituents at the 3-position, are selective ligands for GABAA receptors, in particular having high affinity for the &agr;2 and/or &agr;3 and/or &agr;5 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.
    Type: Grant
    Filed: February 20, 2002
    Date of Patent: July 15, 2003
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: William Robert Carling, Jose Luis Castro Pineiro, Andrew Mitchinson, Leslie Joseph Street
  • Nucleic acid molecule encoding a melanin-concentrating hormone receptor 2 polypeptide
    Patent number: 6593108
    Abstract: The present invention features HG67 nucleic acids and HG67 polypeptides. HG67, also referred to herein as “MCH-R2”, is a G-protein coupled receptor having a high degree of sequence identity with MCH-R1. The amino acid sequence for HG67 is provided by SEQ. ID. NO. 1. The cDNA sequence of HG67 is provided by SEQ. ID. NO. 2.
    Type: Grant
    Filed: November 14, 2000
    Date of Patent: July 15, 2003
    Assignees: Merck & Co., Inc., Banyu Pharmaceutical Co., Ltd.
    Inventors: Qingyun Liu, Terrence P. McDonald, Andrew D. Howard
  • N-cyclopentyl modulators of chemokine receptor activity
    Patent number: 6593346
    Abstract: The present invention is directed to compounds of the formula I: (wherein R1, R3, R4, R5, R6, R7, R8, X, n, x and y are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.
    Type: Grant
    Filed: February 14, 2002
    Date of Patent: July 15, 2003
    Assignee: Merck & Co. Inc.
    Inventors: Paul E. Finke, Kerry A. Hilfiker, Malcolm MacCoss, Kevin T. Chapman, Jennifer L. Loebach, Sander G. Mills, Ravi N. Guthikonda, Shrenik K. Shah, Dooseop Kim, Dong-Ming Shen, Bryan Oates
  • Polymer-based material comprising silica particles
    Publication number: 20030129257
    Abstract: The invention describes a process for the preparation of a polymer-based material consisting of a polyolefin matrix and silica particles as filling material, in which the silica particles are incorporated during the polymerization process. In addition, the uses of a polymer-based material for the production of joint implants in the medicotechnical area and also the use for the production of sliding bearings, gearwheels and other applications in the industrial sector are described. The invention furthermore describes an artificial joint of a prosthesis in which the joint partners consist of metallic, polymeric and/or ceramic materials, with at least one of the joint partners consisting of a polymeric material made from polyolefins with addition of from 1 to 50% by weight of SiO2.
    Type: Application
    Filed: December 9, 2002
    Publication date: July 10, 2003
    Applicant: Merck Patent GmbH
    Inventors: Berthold Nies, Matthias Koch, Holger Winkler
  • Liquid-crystalline mixtures
    Publication number: 20030127629
    Abstract: A liquid-crystalline mixture that contains one or more compounds of each of the formulae IA, IB and IC 1
    Type: Application
    Filed: July 26, 2002
    Publication date: July 10, 2003
    Applicant: Merck Patent GmbH
    Inventors: Harald Hirschmann, Volker Reiffenrath, Marcus Reuter, Sabine Schoen, Sven Schupfer, Clarissa Weller
  • Alpha-hydroxy-gamma-[[(carbocyclic-or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives and uses thereof
    Patent number: 6589962
    Abstract: Certain &agr;-hydroxy-&ggr;-[[(carbocyclic- or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives are described as inhibitors of HIV protease and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described. These compounds are effective against HIV viral mutants which are resistant to HIV protease inhibitors currently used for treating AIDS and HIV infection.
    Type: Grant
    Filed: April 16, 2002
    Date of Patent: July 8, 2003
    Assignee: Merck & Co., Inc.
    Inventors: James R Tata, Zhijian Lu, Subharekha Raghavan, Tracy T. Huening, Thomas A. Rano, Mark G. Charest
  • Adsorption powder for removing mercury from high temperature, high moisture gas streams
    Patent number: 6589318
    Abstract: An adsorption powder for removing mercury and other metals, dioxins, furans and other organic compounds from metal- and organic compound-comtaminated soil and method therefor. The adsorption powder may be characterized as containing from about 1 to 97% of carbon, from about 1 to 97% of calcium hydroxide, from about 1 to 97% of cupric chloride, and from about 1 to 60% of KI3 impregnated carbon.
    Type: Grant
    Filed: September 29, 1999
    Date of Patent: July 8, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Youssef El-Shoubary, Rudy Maes, Subash C. Seth
  • Mono-, oligo- and polymers comprising a 2,6-azulene group and their use as charge transport materials
    Publication number: 20030122479
    Abstract: Conjugated mono-, oligo- and polyazulenes are suitable for use as semiconductors or charge transport materials in optical, electrooptical or electronic devices including field effect transistors, electroluminescent, photovoltaic and sensor devices, and as field effect transistors and semi-conducting components.
    Type: Application
    Filed: December 10, 2002
    Publication date: July 3, 2003
    Applicant: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Louise Diane Farrand, Michael Findlater, Mark Giles, Martin Heeney, Steven Tierney, Marcus Thompson, Maxim Shkunov, David Sparrowe, Iain McCulloch
  • Methods for inhibiting bone resorption
    Patent number: 6586457
    Abstract: The present invention relates to methods for inhibiting bone resorption in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of an EP4 receptor subtype antagonist.
    Type: Grant
    Filed: March 26, 2001
    Date of Patent: July 1, 2003
    Assignees: Merck & Co., Inc., Merck Frosst Canada & Co.
    Inventors: Shun-Ichi Harada, Mohamed MacHwate, Gideon A. Rodan, Marc Labelle, Kathleen Metters, Robert N. Young
  • Tyrosine kinase inhibitors
    Patent number: 6586423
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: February 1, 2002
    Date of Patent: July 1, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, George D. Hartman, Peter J. Manley, Randall W. Hungate, Leonard Rodman
  • C1 to C4 side chain modified nodulisporic acid analogs
    Patent number: 6586452
    Abstract: The present invention relates to novel nodulosporic acid derivatives, which are acaricidal, antiparasitic, insecticidal and anthelmintic agents.
    Type: Grant
    Filed: July 9, 2001
    Date of Patent: July 1, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Thomas Shih, Steven L. Colletti, Michael H. Fisher, Peter T. Meinke, Howard C. H. Kuo, Prasun K. Chakravarty, Matthew J. Wyvratt, Sriram Tyagarajan, Richard Berger
  • Tyrosine kinase inhibitors
    Patent number: 6586424
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: February 1, 2002
    Date of Patent: July 1, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, George D. Hartman, Peter J. Manley
  • Inhibitor of vascular endothelial cell growth factor
    Publication number: 20030120038
    Abstract: The vascular endothelial cell growth factor (VEGF) inhibitors of the present invention are naturally occurring or recombinantly engineered soluble forms with or without a C-terminal transmembrane region of the receptor for VEGF, a very selective growth factor for endothelial cells. The soluble forms of the receptors will bind the growth factor with high affinity but do not result in signal transduction. These soluble forms of the receptor bind VEGF and inhibit its function.
    Type: Application
    Filed: March 19, 2002
    Publication date: June 26, 2003
    Applicant: Merck & Co., Inc.
    Inventors: Richard L. Kendall, Kenneth A. Thomas
  • DNA molecules encoding human nuclear receptor proteins
    Publication number: 20030119100
    Abstract: The present invention discloses the isolation and characterization of cDNA molecules encoding two human nuclear receptor proteins, designated nNR1, nNR2 and/or nNR2-1. Also within the scope of the disclosure are recombinant vectors, recombinant host cells, methods of screening for modulators of nNR1, nNR2 and/or nNR2-1 activity, and production of antibodies against nNR1, nNR2 and/or nNR2-1, or epitopes thereof.
    Type: Application
    Filed: January 23, 2002
    Publication date: June 26, 2003
    Applicant: Merck & Co., Inc.
    Inventor: Fang Chen
  • Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)
    Patent number: 6583126
    Abstract: The invention encompasses the novel class of compounds represented by formula I which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and diabetes-related diseases.
    Type: Grant
    Filed: December 21, 2000
    Date of Patent: June 24, 2003
    Assignee: Merck Erosst Canada & Co.
    Inventors: Yves Leblanc, Claude Dufresne, Scheigetz John, Cheuk Kun Lau, Chun Sing Li, Patrick Roy, Michael Boyd, Zhaoyin Wang